Completed PHASE4 INTERVENTIONAL 2-arm NCT02729012

Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With AR. RinASol- Pilot Study (RinASol)

Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With Allergic Rhinitis. RinASol- Pilot Study (Allergic Rhinitis Solution)

Sponsor: Stefania La Grutta, MD

Conditions Allergic Rhinitis

Interventions Saline Solution (NACL 0,9%) hypertonic saline solution (NACL 3%+NAHCO3)

Updated 6 times since 2017 Last updated: Jan 11, 2017 Started: Oct 31, 2015 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02729012, this PHASE4 trial focuses on Allergic Rhinitis and remains completed. Sponsored by Stefania La Grutta, MD, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jul 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Jul 2019 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stefania La Grutta, MD

Data source: Istituto per la Ricerca e l'Innovazione Biomedica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Palermo, Italy